<p>Sinovac said its Covid-19 vaccine is safe in children ages 3-17, based on preliminary data, and it has submitted the data to Chinese drug regulators.</p>.<p>More than 70 million shots of Sinovac's vaccine have been given worldwide, including in China.</p>.<p>China has approved its use in adults but it has not yet been used in children, because their immune systems may respond differently to the vaccine.</p>.<p>Early and mid-stage clinical trials with over 550 subjects showed the vaccine would induce an immune response, Gang Zeng, the medical director at Sinovac, said at a news conference Monday.</p>.<p><strong>Read more: <a href="https://www.deccanherald.com/international/world-news-politics/covid-19-vaccine-more-effective-with-longer-dose-interval-says-chinas-sinovac-940486.html" target="_blank">Covid-19 vaccine more effective with longer dose interval, says China's Sinovac</a></strong></p>.<p>Two recipients developed high fevers in response to the vaccine, one a 3-year-old and the other a 6-year-old. The rest of the trial subjects experienced mild symptoms, Zeng said.</p>.<p>“Showing that the vaccine is safe and would elicit potentially useful immune response against SARS-CoV-2 is very welcomed,” said Eng Eong Ooi, a professor at the Duke NUS Medical school in Singapore who is co-leading the development of a separate Covid-19 vaccine.</p>.<p>However, he said the data presented publicly by the company was not enough to give a conclusive answer on the findings.</p>.<p>Children are far less likely to be seriously ill with Covid-19, but they are still at risk and can spread the virus. And while vaccination campaigns worldwide have focused on adults, children will need to be immunized to end the pandemic.</p>.<p>The Pfizer vaccine is cleared for use starting at age 16 and is being studied in ages 12-16.</p>.<p>Moderna has been studying its vaccine in children aged 12 and older, and last week announced a new study testing its use in children younger than 12.</p>.<p>State-owned Sinopharm, who has two Covid-19 vaccines, is also investigating the effectiveness of its vaccines in children.</p>.<p>The company said in January it had submitted clinical data to regulators, though it was unclear if it was for one or both vaccines.</p>
<p>Sinovac said its Covid-19 vaccine is safe in children ages 3-17, based on preliminary data, and it has submitted the data to Chinese drug regulators.</p>.<p>More than 70 million shots of Sinovac's vaccine have been given worldwide, including in China.</p>.<p>China has approved its use in adults but it has not yet been used in children, because their immune systems may respond differently to the vaccine.</p>.<p>Early and mid-stage clinical trials with over 550 subjects showed the vaccine would induce an immune response, Gang Zeng, the medical director at Sinovac, said at a news conference Monday.</p>.<p><strong>Read more: <a href="https://www.deccanherald.com/international/world-news-politics/covid-19-vaccine-more-effective-with-longer-dose-interval-says-chinas-sinovac-940486.html" target="_blank">Covid-19 vaccine more effective with longer dose interval, says China's Sinovac</a></strong></p>.<p>Two recipients developed high fevers in response to the vaccine, one a 3-year-old and the other a 6-year-old. The rest of the trial subjects experienced mild symptoms, Zeng said.</p>.<p>“Showing that the vaccine is safe and would elicit potentially useful immune response against SARS-CoV-2 is very welcomed,” said Eng Eong Ooi, a professor at the Duke NUS Medical school in Singapore who is co-leading the development of a separate Covid-19 vaccine.</p>.<p>However, he said the data presented publicly by the company was not enough to give a conclusive answer on the findings.</p>.<p>Children are far less likely to be seriously ill with Covid-19, but they are still at risk and can spread the virus. And while vaccination campaigns worldwide have focused on adults, children will need to be immunized to end the pandemic.</p>.<p>The Pfizer vaccine is cleared for use starting at age 16 and is being studied in ages 12-16.</p>.<p>Moderna has been studying its vaccine in children aged 12 and older, and last week announced a new study testing its use in children younger than 12.</p>.<p>State-owned Sinopharm, who has two Covid-19 vaccines, is also investigating the effectiveness of its vaccines in children.</p>.<p>The company said in January it had submitted clinical data to regulators, though it was unclear if it was for one or both vaccines.</p>